Kindred Biosciences, Inc. (KIN)
Chart Events
Performance Outlook
| Previous Close | 4.8300 |
| Open | 4.8500 |
| Bid | 4.7600 x 2200 |
| Ask | 4.7400 x 1000 |
| Day's Range | 4.7100 - 4.9500 |
| 52 Week Range | 3.2000 - 6.0000 |
| Volume | 207,417 |
| Avg. Volume | 478,586 |
| Market Cap | 205.119M |
| Beta (5Y Monthly) | 1.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5550 |
| Earnings Date | Mar 16, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.18 |
- PR Newswire
Kindred Biosciences Unveils Positive Results from its Long-Acting Interleukin-31 Antibody PK Study
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today unveiled positive results in a new long-acting interleukin (IL)-31 antibody program (KIND-039) that integrates the company's novel half-life extension technology. Results from the pharmacokinetic study of the molecule demonstrate that the fully caninized, high-affinity antibody has up to a three-fold longer half-life compared to tirnovetmab. This extended half-life is expected to allow for up to three-fold longer interval between dosing.
- Zacks
Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates
Kindred Bio (KIN) delivered earnings and revenue surprises of 15.15% and -0.94%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Kindred Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided updates on its programs. For the fourth quarter of 2020, KindredBio reported net revenues of $1.0 million and a net loss of $10.9 million, or $0.28 per share. For the full year 2020, net product revenues were $42.2 million and the net loss was $21.8 million, or $0.55 per share.
